Role And Frequency Of Non-Viral Causes In Chronic Liver Disease And Cirrhosis

Main Article Content

FNU Savanti
Sanjna Devi
Kajol Kumari
Anushka Andani


Chronic Liver Disease, cirrhosis, non-viral triggers, excessive alcohol use, metabolic syndrome.


The existing understanding of Chronic Liver Disease (CLD) and cirrhosis has primarily revolved around viral origins, particularly Hepatitis B and C. However, recent research highlights the significant impact of non-viral factors. This study aimed to comprehensively examine and quantify the prevalence and influence of non-viral elements involved in the development and progression of CLD and cirrhosis.
Our research employed a comprehensive methodology, encompassing a meticulous analysis of patient medical records, physical examinations, laboratory findings, and an extensive exploration of various lifestyle variables. The non-viral factors investigated included excessive alcohol consumption, components of metabolic syndrome, autoimmune disorders, drug-induced liver damage, and exposure to environmental toxins. The diverse demographic representation of our study cohort ensured the broad applicability of our findings.
Our findings unequivocally demonstrate that non-viral influences play a substantial role in the onset and progression of CLD and cirrhosis, surpassing previous recognition. Specifically, excessive alcohol use and components of metabolic syndrome emerged as primary non-viral contributors, exhibiting strong associations with disease development and progression. While autoimmune disorders were less prevalent, they displayed significant impact within a specific subset of patients. Additionally, cases of drug-induced liver damage and exposure to environmental toxins exhibited notable correlations.
These groundbreaking findings offer fresh insights into the complex etiology of CLD and cirrhosis, emphasizing the need to shift our attention towards non-viral causes. This enhanced understanding serves as a critical foundation for implementing improved preventive strategies, refining early detection methods, and developing personalized treatment plans, thus advancing the field of liver disease research and clinical care.

Abstract 193 | Pdf Downloads 63


1. Younossi, Z., Anstee, Q. M., Marietti, M., Hardy, T., Henry, L., Eslam, M., ... & Bugianesi, E. (2018). Global burden of NAFLD and NASH: trends, predictions, risk factors and prevention. Nature Reviews Gastroenterology & Hepatology, 15(1), 11-20.
2. Younossi, Z. M., Koenig, A. B., Abdelatif, D., Fazel, Y., Henry, L., & Wymer, M. (2016). Global epidemiology of nonalcoholic fatty liver disease—Meta‐analytic assessment of prevalence, incidence, and outcomes. Hepatology, 64(1), 73-84.
3. Younossi, Z., Tacke, F., Arrese, M., Chander Sharma, B., Mostafa, I., Bugianesi, E., ... & George, J. (2019). Global perspectives on nonalcoholic fatty liver disease and nonalcoholic steatohepatitis. Hepatology, 69(6), 2672-2682.
4. Younossi, Z. M., Stepanova, M., Negro, F., Hallaji, S., Younossi, Y., Lam, B., & Srishord, M. (2012). Nonalcoholic fatty liver disease in lean individuals in the United States. Medicine, 91(6), 319-327.
5. Caparrós, E., & Francés, R. (2018). The Interleukin-20 Cytokine Family in Liver Disease. Frontiers in Immunology, 9, 1155.
6. Chan, W. K., & Wong, V. W. (2022). Meaning of non‐overlapping patients between the MAFLD and NAFLD definitions. Liver International.
7. Polis, S. J., & Fernandez, R. (2015). Impact of physical and psychological factors on health‐related quality of life in adult patients with liver cirrhosis: a systematic review protocol. JBI Database of Systematic Reviews and Implementation Reports, 13(2), 14-26.
8. Barton, J. C., Patel, N., & McLaren, G. (2021). Abdominal pain and cirrhosis at diagnosis of hemochromatosis: Analysis of 219 referred probands with HFE p.C282Y homozygosity and a literature review. PloS one, 16(12), e0261690.
9. Tsochatzis, E. A., Bosch, J., & Burroughs, A. K. (2014). Liver cirrhosis. The Lancet, 383(9930), 1749-1761.
10. Schuppan, D., & Afdhal, N. H. (2008). Liver cirrhosis. The Lancet, 371(9615), 838-851.
11. Mokdad, A. A., Lopez, A. D., Shahraz, S., Lozano, R., Mokdad, A. H., Stanaway, J., ... & Murray, C. J. (2014). Liver cirrhosis mortality in 187 countries between 1980 and 2010: a systematic analysis. BMC medicine, 12(1), 1-14.
12. Scaglione, S., Kliethermes, S., Cao, G., Shoham, D., Durazo, R., Luke, A., & Volk, M. L. (2015). The epidemiology of cirrhosis in the United States: a population-based study. Journal of Clinical Gastroenterology, 49(8), 690-696.
13. Asrani, S. K., Devarbhavi, H., Eaton, J., & Kamath, P. S. (2019). Burden of liver diseases in the world. Journal of hepatology, 70(1), 151-171.
14. Tapper, E. B., & Parikh, N. D. (2018). Mortality due to cirrhosis and liver cancer in the United States, 1999-2016: observational study. Bmj, 362.
15. D'Amico, G., Garcia-Tsao, G., & Pagliaro, L. (2006). Natural history and prognostic indicators
of survival in cirrhosis: a systematic review of 118 studies. Journal of hepatology, 44(1), 217-231.
16. GBD 2017 Cirrhosis Collaborators. (2020). The global, regional, and national burden of cirrhosis by cause in 195 countries and territories, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017. The Lancet Gastroenterology & Hepatology, 5(3), 245-266.
17. Schuppan, D., & Kim, Y. O. (2013). Evolving therapies for liver fibrosis. Journal of Clinical Investigation, 123(5), 1887-1901.
18. Friedman, S. L. (2008). Mechanisms of hepatic fibrogenesis. Gastroenterology, 134(6), 1655-1669.
19. Bataller, R., & Brenner, D. A. (2005). Liver fibrosis. Journal of Clinical Investigation, 115(2), 209-218.
20. Trautwein, C., Friedman, S. L., Schuppan, D., & Pinzani, M. (2015). Hepatic fibrosis: Concept to treatment. Journal of hepatology, 62(1), S15-S24.
21. Marcellin, P., & Kutala, B. K. (2018). Liver diseases: A major, neglected global public health problem requiring urgent actions and large-scale screening. Liver International, 38, 2-6.
22. Brunner, S. F., Roberts, N. D., Wylie, L. A., Moore, L., Aitken, S. J., Davies, S. E., ... & Campbell, P. J. (2019). Somatic mutations and clonal dynamics in healthy and cirrhotic human liver. Nature, 574(7779), 538-542.
23. Rigopoulou, E. I., & Dalekos, G. N. (2021). Current Trends and Characteristics of Hepatocellular Carcinoma in Patients with Autoimmune Liver Diseases. Cancers, 13(5), 1023.
24. Fifield, B. A., Talia, J., Stoyanovich, C., Elliott, M., Bakht, M. K., Basilious, A., ... & Porter, L. A. (2020). Cyclin-Like Proteins Tip Regenerative Balance in the Liver to Favour Cancer Formation. Carcinogenesis, 41(6), 850-860.